Abstract
Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Anilides / administration & dosage*
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Drug Resistance, Neoplasm / genetics*
-
Humans
-
Imidazoles / administration & dosage*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Pyridazines / administration & dosage*
-
Pyridines / administration & dosage*
Substances
-
Anilides
-
HhAntag691
-
Imidazoles
-
Pyridazines
-
Pyridines
-
ponatinib